RENEURON GRP (RENE.L, LSE, LSE:RENE)
RENE Share PerformanceMore
|52 week high||5.700 13/05/15|
|52 week low||2.750 16/06/14|
|52 week change||2.498 (83.55%)|
|4 week volume||227,060,977 01/05/15|
Media for (RENE)
Latest News« previous» nextMore
22/05/2015 - 07:23 StockMarketWire
ReNeuron Group said the US Food and Drug Administration (FDA) has granted Fast Track designation to its human Retin...
22/05/2015 - 07:00 RNS
RNS Number: 0170O ReNeuron Group plc 22 May 2015 22 May 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") FDA grants Fast Track designation to ReNeuron's retinitis pigmentosa cell therapy candidate Guildford, UK, 22 May 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that ...
15/05/2015 - 07:00 RNS
RNS Number: 2503N ReNeuron Group plc 15 May 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: RENEURON PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition o...
07/05/2015 - 07:00 RNS
RNS Number: 4067M ReNeuron Group plc 07 May 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ReNeuron Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisi...
05/05/2015 - 07:01 RNS
RNS Number: 1472M ReNeuron Group plc 05 May 2015 5 May 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") FDA gives ReNeuron approval to start a Phase I/II clinical trial in the US in retinitis pigmentosa Guildford, UK, 5 May 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces tha...
22/04/2015 - 16:40 RNS
RNS Number: 0450L ReNeuron Group plc 22 April 2015 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determi...
22/04/2015 - 16:35 RNS
RNS Number: 0434L ReNeuron Group plc 22 April 2015 Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's closing auction call bef...
17/04/2015 - 12:25 StockMarketWire
ReNeuron Group, a leading UK-based stem cell therapy company, has provided a further and final update on the PISCES...
|Dividend yield||0 %|
Equity Research (RENE)
ReNeuron Group plc
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....
ReNeuron Group plc
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
ReNeuron Group plc
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...
- 1 of 2
Latest discussion posts More
Codes & Symbols
|Symbols||RENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE|